For the year ending 2025-12-31, CGEM had $5,327K increase in cash & cash equivalents over the period. -$175,799K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -219,879 |
| Equity-based compensation expense | 36,040 |
| Accretion on marketable securities | -6,306 |
| Depreciation and amortization | 311 |
| Prepaid expenses and other current assets | -6,897 |
| Accounts payable | -839 |
| Accrued expenses and other liabilities | 8,026 |
| Net cash used in operating activities | -175,750 |
| Maturities of marketable securities | 416,572 |
| Purchase of marketable securities | 236,534 |
| Purchase of property and equipment | 49 |
| Net cash provided by (used in) investing activities | 179,989 |
| Issuance of common stock under equity-based compensation plans | 1,088 |
| Issuance of common stock and pre-funded warrants, net of issuance costs | 0 |
| Acquisition of noncontrolling interests | 0 |
| Net cash provided by financing activities | 1,088 |
| Net decrease in cash and cash equivalents | 5,327 |
| Cash and cash equivalents at beginning of period | 83,005 |
| Cash and cash equivalents at end of period | 88,332 |
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)